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The Antimicrobial Protein Psoriasin (S100A7) Is
Upregulated in Atopic Dermatitis and after
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Regina Fo¨lster-Holst1, Ehrhardt Proksch1, Jens-Michael Schro¨der1 and Thomas Schwarz1
The innate defense of the skin against microbial threats is influenced by antimicrobial proteins (AMP).
Staphylococcus aureus often colonizes the skin of patients with atopic dermatitis (AD). This was explained by
diminished expression of AMP including cathelicidin/LL-37, human b-defensins-2 and -3, and dermcidin. The
S100-protein psoriasin is an additional keratinocyte-derived AMP that preferentially kills E. coli. As E. coli
infections are not observed in atopic skin we investigated the functional role of psoriasin in AD patients.
Immunohistochemistry demonstrated enhanced epidermal psoriasin expression in AD. An up to 1500-fold
increase in secreted psoriasin was detected by ELISA in vivo on the surface of AD skin compared to healthy
control skin. Surprisingly, tumor necrosis factor-a-enhanced psoriasin release in primary keratinocytes was
inhibited by the Th2-cytokines IL-4 and -13, whereas IL-17 and -22 induced psoriasin. Epidermal barrier
disruption significantly enhanced psoriasin expression as demonstrated by tape stripping in healthy volunteers.
The upregulation of psoriasin in AD maybe induced by the disrupted skin barrier offering a possible
explanation why these patients do not suffer from skin infections with E. coli. This indicates that the
antimicrobial response in AD is not generally impaired, but greatly differs according to the type of AMP
produced by the skin.
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INTRODUCTION
In general, the epidermis is constantly exposed to a variety of
microbial challenges. The permeability barrier, localized in
the stratum corneum, is a mechanical protective hurdle
against bacterial infection. The first column in antimicrobial
defense is the physical barrier in the stratum corneum, which
is supported by the (normal) microflora, antimicrobial lipids,
and antimicrobial proteins (AMP; Bibel et al., 1989; Elias,
2007; Jensen et al., 2007; Aberg et al., 2008). Impairment of
the physical barrier by injury is a prerequisite for experi-
mental skin infection by the application of a bacterial
suspension (Singh et al., 1971). In atopic dermatitis (AD)
and psoriasis vulgaris, skin diseases that are associated with a
disturbed permeability barrier function, the epidermis is
colonized with a higher rate and potentially pathogenic
microorganisms (Aly et al., 1976, 1977; Leung, 2003; Baker,
2006). In a mouse model with a chronically impaired skin
barrier induced by an essential fatty acid-deficient diet,
microbial colonization with Staphylococcus aureus was
enhanced (Bibel et al., 1989).
Despite significant changes in bacterial colonization and
an impaired permeability barrier, psoriatic epidermis is
usually free of the symptoms of infection (Henseler and
Christophers, 1995), whereas in AD, clinical signs of
impetiginization are predominantly found in severe cases
and after extensive scratching (Lubbe, 2003). Nevertheless,
both diseases can be aggravated by bacterial ‘‘superantigens’’
that bypass the normal control of T-cell activation (Skov and
Baadsgaard, 2000) and colonization with superantigen- and
toxin-producing S. aureus can aggravate the disease.
The unexpected low incidence of infections in psoriatic
skin suggests additional cutaneous defense mechanisms
besides the physical barrier. One of these defense mechan-
isms comprises the production of AMP, which are found
abundant in lesional psoriatic scales (Harder and Schro¨der,
2005a, b) and are generated by various epithelial cells
(reviewed in (Ganz and Lehrer, 1998; Schro¨der and Harder,
2006)). Several types of AMP including the human b-
defensins (hBD) 1–3 (Fulton et al., 1997; Harder et al.,
1997, 2001, 2004), the cathelicidin LL-37 (Frohm et al.,
1997), dermcidin (Schittek et al., 2001), RNase-7 (Harder and
Schro¨der, 2002), and psoriasin (Gla¨ser et al., 2005) were
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identified in human skin. Keratinocyte-derived AMPs protect
healthy skin from surrounding microorganisms and may
regulate the composition of the normal flora (Dinulos et al.,
2003; Chung and Dale, 2004). Some of the AMPs (hBD-1,
RNase-7, lysozyme) are constitutively expressed by keratino-
cytes (Harder et al., 2007). A few—such as psoriasin—are
focally present at different levels in healthy skin (Gla¨ser et al.,
2005) and inducible upon skin inflammation (Madsen et al.,
1991) or wounding (Lee and Eckert, 2007), whereas others
(hBD-2, -3, LL-37) are found only in inflamed but not in
healthy skin (Abiko et al., 2002; Sorensen et al., 2003, 2005;
Li et al., 2004; Harder and Schro¨der, 2005a, b). AMP are
inducible by proinflammatory cytokines including IL-1b,
tumor necrosis factor-a (TNF-a) (Harder et al., 2000, 2004),
IL-17 and -22 (Liang et al., 2006; Wolk et al., 2006), after
bacterial contact (Harder et al., 2000; Kisich et al., 2007),
during epidermal differentiation (Harder et al., 2004) or
wound healing (Sorensen et al., 2003). In addition, the
expression of LL-37 in keratinocytes appears to be induced by
1,25(OH)2 vitamin D3 (Wang et al., 2004; Weber et al.,
2005; Schauber et al., 2007).
Recently, we identified the S100-protein psoriasin as an
additional AMP in healthy human epidermis (Gla¨ser et al.,
2005). At lower doses, psoriasin preferentially kills E. coli. At
higher concentrations, however, it exhibits also bactericidal
activity against Pseudomonas aeruginosa and S. aureus.
Psoriasin, originally identified from psoriatic keratinocytes
(Madsen et al., 1991), is constitutively expressed at rather
high levels in skin and upregulated by proinflammatory
cytokines or bacterial compounds (Gla¨ser et al., 2005).
Psoriasin was also shown to function as a potent T-cell- and
neutrophil-chemotactic agent (Jinquan et al., 1996; Zheng
et al., 2008).
Patients with AD often suffer from skin infections caused
by bacteria and viruses (Leung, 2003; Wollenberg et al.,
2003). Among bacterial superinfections S. aureus is the
predominant pathogen. Approximately 90% of AD patients
were shown to be colonized with S. aureus compared to only
5–30% in a control population (Leung, 2003). Previously
unknown observations suggest that an impaired expression of
AMP may contribute to the increased susceptibility of AD
skin to S. aureus. It has been demonstrated that the AMP
hBD-2 and LL-37 are expressed to a lesser extent in the
epidermis of AD patients, when compared to psoriatic
epidermis (Ong et al., 2002). Another study reported a
disturbed upregulation of hBD-3 in AD skin (Nomura et al.,
2003a, b). This may be of particular importance because
hBD-3 is known to be an important AMP produced by
keratinocytes to control the growth of S. aureus (Kisich et al.,
2007). In addition, the sweat gland-derived AMP dermcidin
was found to be diminished in AD patients (Rieg et al., 2005).
Together, these data support the hypothesis that a deficiency
of AMP could contribute to the increased susceptibility of AD
skin to infection with S. aureus.
Interestingly, AD patients do not suffer from skin infections
caused by E. coli, although this is the most common gut
bacterium (Baker, 2006). On the basis of the recently
discovered potent E. coli-cidal activity (Gla¨ser et al., 2005;
Li et al., 2005), we hypothesized that psoriasin expression
might be increased in AD patients, thereby contributing to the
resistance of atopic epidermis to E. coli infections despite the
impaired epidermal barrier. Here, we show that psoriasin
indeed is enhanced in AD and thus differently regulated than
the other AMP. We also provide evidence that the increased
expression of psoriasin may be driven by the disrupted
epidermal barrier, representing a kind of autoprotective
mechanism.
RESULTS
Psoriasin immunoreactivity and secretion is enhanced in atopic
dermatitis skin in vivo
The expression of psoriasin in the epidermis was first
examined at the protein level by immunostaining using a
specific antibody. For that purpose, biopsies were taken from
four AD patients. Lesional skin of all four patients revealed
increased psoriasin expression compared to nonlesional skin
and control biopsies of healthy volunteers at the same
anatomical localization (Figure 1a). The intensity of psoriasin
immunostaining in the lesional skin of AD patients
was comparable to that found in lesional psoriatic skin
(Figure 1b).
To investigate whether the increased psoriasin expression
in the skin of patients with AD leads to enhanced secretion of
psoriasin, washing fluids of standardized areas of nonlesional
and lesional skin were obtained and analyzed for psoriasin
concentrations using a specific psoriasin ELISA. A markedly
enhanced secretion with up to 1500-fold increase of soluble
psoriasin was observed in the washing fluids derived from AD
lesional skin when compared to nonlesional skin and normal
controls (Figure 2). Notably nonlesional skin exhibited
significantly enhanced levels of secreted psoriasin when
compared to healthy control skin. The difference between
nonlesional and lesional atopic skin was also shown to be
significant (Po0.0005).
TNF-a-induced psoriasin secretion is inhibited by Th2 cytokines
in primary keratinocytes
The Th2 cytokines IL-4 and -13 were found to be increased in
AD skin and have been attributed to be responsible for the
downregulation of hBD-2 and -3 and the cathelicidin LL-37
(Ong et al., 2002; Nomura et al., 2003a, b). Thus, we asked in
turn whether both cytokines are involved in the regulation of
psoriasin as well. To address this issue, cultured primary
keratinocytes were stimulated with the Th2 cytokines IL-4
and -13 alone and in combination with the proinflammatory
cytokine TNF-a that was shown to be upregulated in the
epidermis of patients with AD (Sumimoto et al., 1992;
Ackermann and Harvima, 1998; de Vries et al., 1998;
Junghans et al., 1998; Antunez et al., 2006). Secreted
psoriasin was determined in the supernatants by ELISA
(Figure 3a). Stimulation with TNF-a significantly induced
the release of psoriasin, whereas neither IL-4 nor IL-13 had a
significant impact on the basal psoriasin expression. In
contrast, both IL-4 and -13 markedly inhibited the induction
of psoriasin by TNF-a. The combination of IL-4 and -13 did
not yield an additive or synergistic inhibitory effect.
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IL-17 and -22 induce psoriasin secretion in primary
keratinocytes
As recently a possible pathogenic role of Th17 cells was
reported for AD (Koga et al., 2008), primary keratinocytes
were additionally stimulated with IL-17 and/or -22. An
enhanced secretion of psoriasin was observed 16 hour after
stimulation with both cytokines and the combination of IL-17
and -22 resulted in an additive effect (Figure 3b). Stimulation
of keratinocytes with IL-17 and -22 in the presence of Th2
cytokines IL-4 and -13 did not alter upregulated psoriasin
secretion (data not shown).
Psoriasin secretion is enhanced after experimental disruption of
the skin barrier
As it is known that patients with AD exhibit skin barrier
disruption with enhanced levels of transepidermal water loss
(Loden et al., 1992; Jensen et al., 2004), we hypothesized that
an artificial disruption of the epidermal barrier could lead to
an increase in psoriasin secretion. Indeed, a rapid increase of
soluble psoriasin was observed directly after tape stripping.
Increased soluble psoriasin was measured at nearly constant
levels 30 and 120minutes after skin injury performed in
healthy volunteers (n¼12, Figure 4a). Most interestingly,
secretion of psoriasin remained elevated even 7 days after
skin barrier disruption.
To investigate the influence of experimental barrier repair
on psoriasin expression, additional experiments were per-
formed under occlusion (n¼ 8). Washing fluids collected at
two time points showed enhanced expression 1 and 24 hour
after tape stripping, independently from occlusion (Figure 4b).
Median psoriasin concentrations rose from 2.63 ng/ml
(0.86–7.61) after 1 hour to 10.95 ng/ml (5.26–67.90) without
occlusion (Po0.01) and 5.88 ng/ml (1.87–36.85) under
occlusion. At 24 hour after tape stripping median psoriasin
Psoriasis vulgarisBlocking controlPositive control
Buttock
Buttock
Trunk
Forearm
Control person AD nonlesional skin AD lesional skin
Figure 1. Psoriasin immunoreactivity is enhanced in lesional atopic dermatitis skin. (a) To localize the expression of psoriasin in human skin biopsies
of AD patients and normal controls immunohistochemical staining was performed. Lesional skin of AD patients revealed increased psoriasin expression
compared to nonlesional skin and healthy controls at correlating sites. Bars indicate 50mm. (b) Specificity testing was performed by preincubation of the
antibody with various concentrations of natural skin-derived psoriasin. Blocking the antibody with higher concentrations than 0.06 mg psoriasin resulted in
complete inhibition of immunoreactivity in a tissue sample derived from the face of a healthy person. Immunostaining of psoriasis vulgaris served as a
further positive control. Bars indicate 50 mm.
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concentrations were at 7.52 ng/ml (1.54–27.13) without
(Po0.01) and at 6.33 ng/ml (1.72–14.68) under occlusion.
Differences at 1 hour between both procedures were statis-
tically significant (Po0.05). Spearman’s rank correlation
analyses did not reveal any correlation between transepider-
mal water loss values and psoriasin concentrations in the
individual groups (data not shown).
Accordingly, significantly enhanced psoriasin expression
was also detected by immunohistochemistry in tissue samples
obtained after tape stripping. Biopsies taken 24 hour after
tape stripping (n¼ 2) revealed impressive upregulation of
psoriasin expression in the upper epidermal layers compared
to the untreated control (Figure 4c) derived from the
corresponding localization. Immunoreactivity appeared less
intensive after occlusion (Figure 4c), decreased at later time
points (day 4), and disappeared at day 7 (n¼ 3, data not
shown).
DISCUSSION
Human skin is permanently exposed to a variety of
potentially harmful microorganisms but usually remains free
of infection. The physical barrier is of central importance for
antibacterial defense. However, disruptions of the barrier by
small injuries like scratches are common and do not
necessarily result in skin infection. The importance of
keratinocyte-derived AMP as part of a ‘‘chemical barrier’’ in
healthy and diseased skin is today well established (Nizet
et al., 2001; Elias, 2005, 2007). The identification of various
AMP (hBD-2 (Harder et al., 1997) and -3 (Harder et al.,
2001), psoriasin (Madsen et al., 1991; Gla¨ser et al., 2005),
and calprotectin (Clohessy and Golden, 1995)) from lesional
psoriatic skin might explain the phenomenon that these
patients suffer from significantly fewer skin infections than
expected (Henseler and Christophers, 1995).
In contrast, hBD-2, -3, and LL-37 were shown to be
expressed at decreased levels in acute and chronic lesions
from patients suffering from AD (Ong et al., 2002; Nomura
et al., 2003a, b) when compared with psoriasis vulgaris.
Elevated amounts of Th2 cytokines present in atopic skin
were discussed to cause the inhibition of the expression of
AMP in the inflamed skin, as IL-4 and -13 in vitro suppressed
the cytokine-mediated induction of hBD-2 and -3 (Ong et al.,
2002; Nomura et al., 2003a, b). It was recently shown
that the relative deficiency in hBD-3 expression may be an
acquired defect as neutralization of the Th2 cytokine
milieu in skin explants from AD patients restored the
hBD-3 expression (Howell et al., 2006). The same group
reported that patients with ‘‘extrinsic AD’’, characterized
by elevated serum immunoglobulin E and allergic sensitiza-
tion, as well as patients with ‘‘intrinsic AD’’ showed
both reduced expression of hBD-2, -3, and LL-37 (Howell
et al., 2005, 2006). Additionally, the sweat of subjects
with AD was recently found to be deficient in the sweat
gland-derived AMP dermcidin when compared with
healthy subjects (Rieg et al., 2005). These data suggest
that an impaired induction of AMP may contribute to
the increased susceptibility of skin infections in patients
with AD.
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Figure 3. TNF-a induced psoriasin secretion is inhibited by Th2 cytokines
and Th17 cytokines induce psoriasin secretion in primary keratinocytes.
(a, b) Psoriasin concentration was measured by ELISA in the supernatants of
cultured primary keratinocytes after incubation with different cytokines
(TNF-a, IL-4, and -13: 50 ng/ml, IL-17, and -22: 20 ng/ml) for 16 hour. One
representative out of three independent experiments is shown. Each
stimulation was performed in triplicates. Bars indicate the SEM. Significance
levels were determined in comparison to ‘‘TNF-a-values’’ (a) or the medium
control (b) using the unpaired Student’s t-test. *Po0.05; **Po0.01.
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Figure 2. High concentrations of psoriasin are secreted in atopic dermatitis
(AD) skin. A defined area (0.55 cm2) of the skin of AD patients and matching
normal controls was rinsed with sodium-phosphate buffer (pH 7.4). Soluble
psoriasin concentrations were determined using a psoriasin-specific ELISA
with two mAbs generated against natural psoriasin. Each sample was tested in
triplicates. Bars indicate the median concentration. Groups were compared
using the Wilcoxon matched pairs test (n¼12).
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On the basis of these observations one may conclude that
the antimicrobial response in atopic patients is generally
impaired. However, in this context the fact that AD patients
do not suffer from skin infections caused by the common gut
bacterium E. coli is quite challenging. A first hint of an
induced psoriasin expression in AD was reported by DNA
microarray analysis (Sugiura et al., 2005). Our finding that
psoriasin protein is abundant on AD skin together with the
known high E. coli-killing activity suggests that psoriasin may
contribute to the resistance of atopic epidermis against
colonization and infection with E. coli. The observation that
psoriasin secretion was shown to be significantly upregulated
in lesional and nonlesional AD skin may be explained by the
generally impaired barrier and enhanced microbial coloniza-
tion rate in these patients. The factors that are responsible for
the high induction of psoriasin in AD skin are not known.
Acute lesions of AD are characterized by the overexpression
of Th2 cytokines, especially IL-4 and -13 (Jeong et al., 2003;
Homey et al., 2006). But these cytokines do not appear to be
responsible for the induction of psoriasin in AD as they did
not alter the basal expression of psoriasin in human
keratinocytes in vitro. However, TNF-a-induced upregulation
of psoriasin in cultured keratinocytes was inhibited by
cocultivation of keratinocytes with IL-4 and/or -13. In this
context it has to be mentioned that the role of TNF-a in AD is
controversially discussed and therapeutic inhibition of TNF-a
was shown to be hardly efficient (Nomura et al., 2003a, b;
Buka et al., 2005; Guttman-Yassky et al., 2007; Machura
et al., 2007). On the first glance, these in vitro data may
contradict our in vivo findings. However, the concept that
AD is a purely Th2-driven disease is not any longer valid as it
has been shown that in the chronic phase Th1 cytokines
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Figure 4. Psoriasin secretion is enhanced after experimental disruption of the skin barrier in healthy persons. (a) A defined area (0.55 cm2) of the forearm skin
of healthy volunteers (n¼ 12) was rinsed with sodium-phosphate buffer (pH 7.4) before (‘‘control’’) and after tape stripping at indicated time points. Psoriasin
concentration in 1,000 ml washing fluid was determined using a psoriasin-specific ELISA. Each sample was tested in triplicates. Bars indicate the median
concentration. All time points were compared to the control values using the Wilcoxon matched pairs test. *Po0.05. (b) A defined area (0.55 cm2) of both
forearms of healthy volunteers (n¼ 8) was rinsed with sodium-phosphate buffer (pH 7.4) before (‘‘control’’) and after tape stripping at indicated time points and
the test area of one arm was held under occlusion for 24 hour. Psoriasin concentration in the washing fluids was determined as indicated in (a). Both time points
under investigation were compared to the control values using the Wilcoxon matched pairs test. *Po0.05, **Po0.01. (c) Immunohistochemical analysis of
psoriasin expression in skin biopsies taken 24hour after experimental skin barrier disruption by tape stripping without and under occlusion in comparison to the
untreated control at the same localization (forearm). The upper and lower panels represent two different individuals. Bars indicate 50 mm. SC: Stratum corneum,
E: epidermis, HF: hair follicle.
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appear to be more relevant (Grewe et al., 1994; Leung and
Bieber, 2003). Previously we could demonstrate that IFN-g
and IL-1b are able to induce psoriasin secretion besides TNF-a
(Gla¨ser et al., 2005). Thus, other factors than TNF-a and/or
Th2 cytokines may contribute to the extensive psoriasin
induction observed in the in vivo situation of AD patients.
Th17 cells were identified as a previously unknown subset
of CD4þ T cells, characterized by the production of IL-17 and
coexpression of IL-22 (Harrington et al., 2005; Liang et al.,
2006). Recently, Th17 cells were reported to be increased in
the peripheral blood of AD patients and infiltrated the papillary
dermis of acute atopic skin lesions (Koga et al., 2008). We
demonstrate here that stimulation of primary keratinocytes
with IL-17 and/or -22 resulted in an increased psoriasin
secretion, a phenomenon that has been described before on
the mRNA level (Liang et al., 2006; Wolk et al., 2006). In our
in vitro studies, IL-17 and -22 were the most efficient factors to
stimulate psoriasin secretion. However, one has to be aware
that the definite functional role of Th17 cells and their
cytokines in AD remains to be elucidated.
Another trigger for the upregulation of psoriasin may be
the stimulation by bacteria and their products. Psoriasin was
shown to be induced both in vitro and in vivo by bacterial
culture supernatants (Gla¨ser et al., 2005) and flagellin has
been identified as one of the responsible pathogen-associated
molecular pattern molecule (Abtin et al., 2008). Atopic skin is
colonized by a high density of microorganisms, for example,
for S. aureus 107 organisms per cm2 (Leung, 2003). Thus, it
remains to be determined whether S. aureus or other skin
colonizing bacteria are able to induce psoriasin and why
psoriasin—despite the high concentrations observed in AD
patients in vivo—is not able to control their growth. The
pathogenetic relevance of the chemotactic activity reported
for psoriasin (Jinquan et al., 1996) is still unclear as well.
In addition to our knowledge it is previously unreported
that the disturbed epidermal barrier is a major inducer of
psoriasin expression in vivo. AD is characterized by a
chronically impaired skin barrier function (Jensen et al.,
2004; Rim et al., 2005). One reason for this alteration may be
the reduced expression of filaggrin (Palmer et al., 2006). It
was recently shown in mice that mRNA and protein
expression of murine b-defensin-3 and cathelin-related
antimicrobial peptide, representing the murine homologues
of hBD-2 and LL-37, was increased 1–8 hour after acute
permeability barrier disruption and normalized after 24 hour
(Aberg et al., 2008). The tape stripping experiments
performed in this study are in accordance with these
observations, indicating that skin barrier disruption may be
one of the driving forces of the enhanced psoriasin expression
and secretion in AD skin.
The pronounced and rapid induction of psoriasin may be
an attempt to prevent skin infection in cases of a disrupted
skin barrier. The increase in psoriasin secretion occurred
early within the first 2 hour and maintained elevated up to 7
days. We speculate that preformed psoriasin located in the
stratum corneum is released after experimental skin barrier
disruption in normal controls as well as in diseases with
endogenous skin barrier defects such as psoriasis and AD.
Disruption of the epidermal barrier does not only lead to a
fast release of preformed psoriasin from the stratum corneum,
which is detectable in the washing fluids, but also to a
prolonged protein release on the skin surface over several
days after injury. Complete repair of the permeability barrier
in humans after tape stripping takes about 1 week, implying
that the increased secretion of psoriasin is present during the
entire time frame of the disrupted skin barrier. Interestingly,
experimental barrier repair by occlusion reduced the increase
in psoriasin expression, supporting a direct link between skin
barrier function and psoriasin expression.
This link may also explain the constant overproduction of
psoriasin after experimental wounding. Lee and Eckert (2007)
observed increased expression of psoriasin in wound
exudates and granulation tissue obtained 72 hour after setting
an abrasion wound in one human volunteer. These findings
support the results of our skin barrier disruption experiments
that included a higher number of individuals and also
measured the in vivo secretion of psoriasin shortly after skin
injury over a period of up to 7 days. In conclusion, skin
wounding and barrier disruption may be the key factor
leading to increased psoriasin secretion in AD, whereas the
impact of other factors such as the cytokine milieu or
pathogens remains to be determined.
MATERIALS AND METHODS
Patients and normal controls
In total, 12 Patients (2–41 years, women/men: 8/4) affected by AD
and without specific pretreatment within the last 2 weeks were
included in the study (Table 1). The severity of AD was assessed
Table 1. Characteristics of normal controls and
patients enrolled in the study
Psoriasin concentration
(ng/ml)
No. Sex Age Localization Controls AD:NL AD:L SCORAD
1 M 20 Forearm 1.2 152 185 n.d.
2 F 2 Wrist 20.3 470 1,140 40
3 F 38 Forearm 1.3 87 1,234 23
4 F 3 Arm flexure 23.7 739 4,392 33
5 F 18 Wrist 1.0 23.4 182 18
6 M 37 Trunk 4.9 21.7 109 53
7 F 22 Buttock 3.6 1,252 5,409 69.5
8 F 23 Forearm 12.8 28.1 527 n.d.
9 M 21 Buttock 3.0 476 2,175 33.5
10 F 33 Forearm 3.7 8.2 21.5 49.5
11 F 36 Forearm 5.6 2.3 6.5 23
12 M 41 Lower leg 13.7 40.4 114 n.d.
AD, atopic dermatitis patients; F, female; NL, nonlesional skin (same
localization as L); L, lesional skin; M, male; SCORAD, scoring of atopic
dermatitis; n.d., not done.
Healthy volunteers (controls) and AD patients were matched by gender
and age and washings fluids and biopsies were derived in each case from
the same localization. Therefore sex, age, and localization were only
listed once for both collectives.
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using the ‘‘SCORing Atopic Dermatitis’’ according to the European
Task Force on AD (Kunz et al., 1997). Healthy persons matched by
age and gender were chosen as controls. The study was approved by
the ethical committee of the University Kiel (AZ A 104/06) in
adherence to the Helsinki Guidelines and all patients and healthy
normal controls gave written informed consent.
Collection of skin-derived washing fluids
To determine the active secretion of psoriasin, standardized areas
(0.55 cm2) of untreated lesional and nonlesional skin of AD patients
were rinsed with 900ml of 10mM sodium-phosphate buffer (pH 7.4)
and a corresponding localization was rinsed in the normal controls.
Samples were mixed with 100 ml sodium-phosphate buffer (10mM)
containing 10% (w/v) bovine serum albumin (Sigma, Deisenhofen,
Germany) and supernatants were stored after centrifugation of
samples at 80 1C until further processing.
ELISA
To measure the psoriasin concentrations in skin-derived washing
fluids and in primary keratinocyte culture supernatants, a psoriasin-
specific sandwich ELISA was performed as described previously
(Gla¨ser et al., 2005). A standard curve was created with serial
dilutions of skin-derived psoriasin and all samples were processed in
triplicates. The detection limit was 0.3 ng/ml psoriasin.
Immunohistochemistry
Punch biopsies were taken in local anesthesia from lesional and
nonlesional skin in AD patients (n¼ 4) and normal controls (n¼ 5).
Biopsies derived from the same anatomical localization (mostly
contralateral site in AD patients and comparable site in the controls).
Fixation of the tissue samples was performed in 4% paraformalde-
hyde. To localize the expression of psoriasin in human skin biopsies
of AD patients and controls immunohistochemical staining was
performed. Paraffin sections (5 mm) of the tissue samples were
deparaffinized and rehydrated before heat-induced antigen retrieval
was performed in 0.01M citrate buffer (pH 6.0). The slides were
blocked with normal rabbit serum (1:75, Dako Cytomation,
Glostrup, Denmark) before staining. Immunohistochemical staining
was performed at room temperature for 1 hour using a monoclonal
antibody (HL15-4, kindly provided by Hans Lange, Institute of
Experimental Surgery, University Hospital of Schleswig-Holstein,
Campus Kiel) directed against natural skin-derived psoriasin as
described previously (Gla¨ser et al., 2005). A biotinylated secondary
rabbit anti-mouse IgG (1:100, Dako Cytomation) antibody was used,
followed by incubation with Vector Universal ABC Alkaline
Phosphatase Substrate Kit (Vector, Burlingame, CA, USA) developed
with Vector NovaRED Substrate (Vector) and counterstained with
hematoxylin. Negative control straining was performed by omitting the
primary antibody. Psoriatic lesions served as a positive control as they
exhibit extensive positive staining within the differentiated epithelial
layers from the stratum spinosum up to the stratum corneum. Specificity
was determined by western blotting and by blocking experiments with
preincubation of the antibody and different concentrations of the
antigen as described previously (Gla¨ser et al., 2005).
Keratinocyte culture and stimulation with cytokines
Primary human keratinocytes were prepared from tissue obtained
after plastic surgery procedures as described (Wiedow et al., 1998)
and were grown in EpiLife-Medium (Sigma, Taufkirchen, Germany).
For stimulation, cells were grown in six-well-culture plates (9.6 cm2
per well, Falcon) and were used after the second passage at a
confluence of 70–80%. Cells were stimulated with IL-4 or -13 (50 ng/
ml, PeproTech, Rocky Hill, NJ), IL-17 (20 ng/ml, PeproTech), IL-22
(20 ng/ml, R&D Systems, Wiesbaden, Germany), or TNF-a (50 ng/ml,
PeproTech) for 16 hour and the culture supernatants were harvested
and frozen at 80 1C until further processing by ELISA.
Experimental disruption of the skin barrier
Tape stripping (Tesa Pack original, ultra strong, Tesa Ag, Hamburg,
Germany) of a standardized area of the forearm skin was performed
in healthy volunteers (n¼ 12, 24–48 years, women/men: 7/5) until a
transepidermal water loss of 40 g/m2 per hour monitored by the
Tewameter TM210 (Courage and Khazaka, Cologne, Germany) was
reached. In a second experiment both forearms were treated as
described above (n¼ 8, 25–50 years, women/men: 6/2) and
occlusion was performed on one arm for up to 24 hour after
experimental skin barrier disruption. Large Finn Chambers on
Scanpor were used for effective occlusion (Epitest Ltd. Oy, Tuusula,
Finnland). In vivo washing fluids (10mM sodium-phosphate buffer,
pH 7.4), derived from the untreated forearm and the pretreated area
were collected at different time points, and the amount of psoriasin
was determined by ELISA. Figure 5 demonstrates the experimental
setting. In addition, punch biopsies were taken from the untreated
forearms and 1, 4, or 7 days after skin barrier disruption for
immunohistological analysis of psoriasin expression (n¼ 5).
Statistics
Calculations were performed using Wilcoxon’s signed rank
test (secretion of AMP in vivo), the unpaired Student’s t-test
(expression of psoriasin in vitro) and Spearman’s rank correlation
analysis (correlation of transepidermal water loss and psoriasin
secretion).
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Figure 5. Experimental setting of the in vivo experiments to determine the
active secretion of antimicrobial psoriasin. (a) Determination of the
transepidermal water loss (TEWL) of a standardized area on the forearm
before and during skin barrier disruption. (b) Serial tape-stripping to reach a
TEWL of 40g/m2 per hour. (c) Collection of washing fluids derived from the
untreated forearm and the pretreated area at different time points. (d)
Additional occlusion experiments were performed using Finn Chambers on
Scanpor.
www.jidonline.org 647
R Gla¨ser et al.
Psoriasin in Atopic Dermatitis
ACKNOWLEDGMENTS
We thank Christel Martensen-Kerl, Vera Beck-Jendroschek, Claudia Neu-
mann, and Kerstin Schultz for excellent technical assistance, Michael
Weichenthal for support with statistical analyses, Joachim Bartels and Ulli
Gla¨ser for assistance with the final formatting. Parts of this work are included
in the doctoral thesis of M. Wittersheim and J. Cordes. This study was
supported by grants of the German Research Foundation (DFG, SFB 617 A2,
A3, A7, and A21) given to J. Harder, E. Proksch, J.M. Schro¨der, and
T. Schwarz and grants of the Medical Faculty of Kiel and the Federal Ministry
of Education and Research (BMBF, SkInStaph) given to R. Gla¨ser.
REFERENCES
Aberg KM, Man MQ, Gallo RL, Ganz T, Crumrine D, Brown BE et al. (2008)
Co-regulation and interdependence of the mammalian epidermal
permeability and antimicrobial barriers. J Invest Dermatol 128:
917–925
Abiko Y, Jinbu Y, Noguchi T, Nishimura M, Kusano K, Amaratunga P et al.
(2002) Upregulation of human beta-defensin 2 peptide expression in oral
lichen planus, leukoplakia and candidiasis. An immunohistochemical
study. Pathol Res Pract 198:537–42
Abtin A, Eckhart L, Mildner M, Gruber F, Schro¨der JM, Tschachler E (2008)
Flagellin is the principal inducer of the antimicrobial peptide S100A7c
(psoriasin) in human epidermal keratinocytes exposed to Escherichia
coli. FASEB J 22:2168–76
Ackermann L, Harvima IT (1998) Mast cells of psoriatic and atopic dermatitis
skin are positive for TNF-alpha and their degranulation is associated with
expression of ICAM-1 in the epidermis. Arch Dermatol Res 290:353–9
Aly R, Maibach HE, Mandel A (1976) Bacterial flora in psoriasis. Br J
Dermatol 95:603–6
Aly R, Maibach HI, Shinefield HR (1977) Microbial flora of atopic dermatitis.
Arch Dermatol 113:780–2
Antunez C, Torres MJ, Mayorga C, Corzo JL, Jurado A, Santamaria-Babi LF
et al. (2006) Cytokine production, activation marker, and skin homing
receptor in children with atopic dermatitis and bronchial asthma. Pediatr
Allergy Immunol 17:166–74
Baker BS (2006) The role of microorganisms in atopic dermatitis. Clin Exp
Immunol 144:1–9
Bibel DJ, Miller SJ, Brown BE, Pandey BB, Elias PM, Shinefield HR et al.
(1989) Antimicrobial activity of stratum corneum lipids from normal and
essential fatty acid-deficient mice. J Invest Dermatol 92:632–8
Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S (2005) Etanercept
is minimally effective in 2 children with atopic dermatitis. J Am Acad
Dermatol 53:358–9
Chung WO, Dale BA (2004) Innate immune response of oral and foreskin
keratinocytes: utilization of different signaling pathways by various
bacterial species. Infect Immun 72:352–8
Clohessy PA, Golden BE (1995) Calprotectin-mediated zinc chelation as a
biostatic mechanism in host defence. Scand J Immunol 42:551–6
de Vries IJ, Langeveld-Wildschut EG, van Reijsen FC, Dubois GR, van den
Hoek JA, Bihari IC et al. (1998) Adhesion molecule expression on skin
endothelia in atopic dermatitis: effects of TNF-alpha and IL-4. J Allergy
Clin Immunol 102:461–8
Dinulos JG, Mentele L, Fredericks LP, Dale BA, Darmstadt GL (2003)
Keratinocyte expression of human beta defensin 2 following bacterial
infection: role in cutaneous host defense. Clin Diagn Lab Immunol
10:161–6
Elias PM (2005) Stratum corneum defensive functions: an integrated view.
J Invest Dermatol 125:183–200
Elias PM (2007) The skin barrier as an innate immune element. Semin
Immunopathol 29:3–14
Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, Wigzell H
et al. (1997) The expression of the gene coding for the antibacterial
peptide LL-37 is induced in human keratinocytes during inflammatory
disorders. J Biol Chem 272:15258–63
Fulton C, Anderson GM, Zasloff M, Bull R, Quinn AG (1997) Expression of
natural peptide antibiotics in human skin. Lancet 350:1750–1
Ganz T, Lehrer RI (1998) Antimicrobial peptides of vertebrates. Curr Opin
Immunol 10:41–4
Gla¨ser R, Harder J, Lange H, Bartels J, Christophers E, Schro¨der JM (2005)
Antimicrobial psoriasin (S100A7) protects human skin from Escherichia
coli infection. Nat Immunol 6:57–64
Grewe M, Gyufko K, Schopf E, Krutmann J (1994) Lesional expression of
interferon-gamma in atopic eczema. Lancet 343:25–6
Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Whynot J, Novitskaya I,
Cardinale I et al. (2007) Major differences in inflammatory dendritic cells
and their products distinguish atopic dermatitis from psoriasis. J Allergy
Clin Immunol 119:1210–7
Harder J, Bartels J, Christophers E, Schro¨der JM (1997) A peptide antibiotic
from human skin. Nature 387:861
Harder J, Bartels J, Christophers E, Schro¨der JM (2001) Isolation and
characterization of human beta -defensin-3, a novel human inducible
peptide antibiotic. J Biol Chem 276:5707–13
Harder J, Gla¨ser R, Schro¨der JM (2007) Review: human antimicrobial proteins
effectors of innate immunity. J Endotoxin Res 13:317–38
Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S
et al. (2000) Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta,
but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J
Respir Cell Mol Biol 22:714–21
Harder J, Meyer-Hoffert U, Wehkamp K, Schwichtenberg L, Schro¨der JM
(2004) Differential gene induction of human beta-defensins (hBD-1, -2,
-3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol
123:522–9
Harder J, Schro¨der JM (2002) RNase 7, a novel innate immune defense
antimicrobial protein of healthy human skin. J Biol Chem 277:46779–84
Harder J, Schro¨der JM (2005a) Antimicrobial peptides in human skin. Chem
Immunol Allergy 86:22–41
Harder J, Schro¨der JM (2005b) Psoriatic scales: a promising source for the
isolation of human skin-derived antimicrobial proteins. J Leukoc Biol
77:476–86
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM
et al. (2005) Interleukin 17-producing CD4+ effector T cells develop via
a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol
6:1123–32
Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am
Acad Dermatol 32:982–6
Homey B, Steinhoff M, Ruzicka T, Leung DY (2006) Cytokines and
chemokines orchestrate atopic skin inflammation. J Allergy Clin
Immunol 118:178–89
Howell MD, Boguniewicz M, Pastore S, Novak N, Bieber T, Girolomoni G
et al. (2006) Mechanism of HBD-3 deficiency in atopic dermatitis. Clin
Immunol 121:332–8
Howell MD, Novak N, Bieber T, Pastore S, Girolomoni G, Boguniewicz M
et al. (2005) Interleukin-10 downregulates anti-microbial peptide
expression in atopic dermatitis. J Invest Dermatol 125:738–45
Jensen JM, Folster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S,
Neumann C et al. (2004) Impaired sphingomyelinase activity and
epidermal differentiation in atopic dermatitis. J Invest Dermatol
122:1423–31
Jensen JM, Pfeiffer S, Akaki T, Schro¨der JM, Kleine M, Neumann C et al.
(2007) Barrier function, epidermal differentiation, and human
beta-defensin 2 expression in tinea corporis. J Invest Dermatol 127:
1720–7
Jeong CW, Ahn KS, Rho NK, Park YD, Lee DY, Lee JH et al. (2003) Differential
in vivo cytokine mRNA expression in lesional skin of intrinsic vs extrinsic
atopic dermatitis patients using semiquantitative RT-PCR. Clin Exp
Allergy 33:1717–24
Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B et al.
(1996) Psoriasin: a novel chemotactic protein. J Invest Dermatol
107:5–10
Junghans V, Gutgesell C, Jung T, Neumann C (1998) Epidermal cytokines
IL-1beta, TNF-alpha, and IL-12 in patients with atopic dermatitis: response
to application of house dust mite antigens. J Invest Dermatol 111:1184–8
648 Journal of Investigative Dermatology (2009), Volume 129
R Gla¨ser et al.
Psoriasin in Atopic Dermatitis
Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DY
(2007) The constitutive capacity of human keratinocytes to kill
Staphylococcus aureus is dependent on beta-defensin 3. J Invest
Dermatol 127:2368–80
Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y (2008) Possible
pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol,
e-pub ahead of print
Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A (1997) Clinical
validation and guidelines for the SCORAD index: consensus report of the
European Task Force on Atopic Dermatitis. Dermatology 195:10–9
Lee KC, Eckert RL (2007) S100A7 (Psoriasin)—mechanism of antibacterial
action in wounds. J Invest Dermatol 127:945–57
Leung DY (2003) Infection in atopic dermatitis. Curr Opin Pediatr 15:399–404
Leung DY, Bieber T (2003) Atopic dermatitis. Lancet 361:151–60
Li D, Li J, Duan Y, Zhou X (2004) Expression of LL-37, human beta defensin-2,
and CCR6 mRNA in patients with psoriasis vulgaris. J Huazhong Univ
Sci Technolog Med Sci 24:404–6
Li X, de Leeuw E, Lu W (2005) Total chemical synthesis of human psoriasin by
native chemical ligation. Biochemistry 44:14688–94
Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K,
Collins M et al. (2006) Interleukin (IL)-22 and IL-17 are coexpressed by
Th17 cells and cooperatively enhance expression of antimicrobial
peptides. J Exp Med 203:2271–9
Loden M, Olsson H, Axell T, Linde YW (1992) Friction, capacitance and
transepidermal water loss (TEWL) in dry atopic and normal skin. Br J
Dermatol 126:137–41
Lubbe J (2003) Secondary infections in patients with atopic dermatitis. Am J
Clin Dermatol 4:641–54
Machura E, Mazur B, Kwiecien J, Karczewska K (2007) Intracellular
production of IL-2, IL-4, IFN-gamma, and TNF-alpha by peripheral
blood CD3+ and CD4+ T cells in children with atopic dermatitis. Eur J
Pediatr 166:789–95
Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E et al.
(1991) Molecular cloning, occurrence, and expression of a novel
partially secreted protein ‘‘psoriasin’’ that is highly up-regulated in
psoriatic skin. J Invest Dermatol 97:701–12
Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA et al.
(2001) Innate antimicrobial peptide protects the skin from invasive
bacterial infection. Nature 414:454–7
Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, Leung DY (2003a)
Distinct patterns of gene expression in the skin lesions of atopic
dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin
Immunol 112:1195–202
Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF et al. (2003b)
Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin
prevents induction of innate immune response genes. J Immunol
171:3262–9
Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T et al.
(2002) Endogenous antimicrobial peptides and skin infections in atopic
dermatitis. N Engl J Med 347:1151–60
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP et al.
(2006) Common loss-of-function variants of the epidermal barrier protein
filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet
38:441–6
Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K et al. (2005)
Deficiency of dermcidin-derived antimicrobial peptides in sweat of
patients with atopic dermatitis correlates with an impaired innate
defense of human skin in vivo. J Immunol 174:8003–10
Rim JH, Jo SJ, Park JY, Park BD, Youn JI (2005) Electrical measurement of
moisturizing effect on skin hydration and barrier function in psoriasis
patients. Clin Exp Dermatol 30:409–13
Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D et al.
(2007) Injury enhances TLR2 function and antimicrobial peptide
expression through a vitamin D-dependent mechanism. J Clin Invest
117:803–11
Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S et al. (2001)
Dermcidin: a novel human antibiotic peptide secreted by sweat glands.
Nat Immunol 2:1133–7
Schro¨der JM, Harder J (2006) Antimicrobial skin peptides and proteins. Cell
Mol Life Sci 63:469–86
Singh G, Marples RR, Kligman AM (1971) Experimental Staphylococcus
aureus infections in humans. J Invest Dermatol 57:149–62
Skov L, Baadsgaard O (2000) Bacterial superantigens and inflammatory skin
diseases. Clin Exp Dermatol 25:57–61
Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N
(2003) Wound healing and expression of antimicrobial peptides/
polypeptides in human keratinocytes, a consequence of common growth
factors. J Immunol 170:5583–9
Sorensen OE, Thapa DR, Rosenthal A, Liu L, Roberts AA, Ganz T (2005)
Differential regulation of {beta}-defensin expression in human skin by
microbial stimuli. J Immunol 174:4870–9
Sugiura H, Ebise H, Tazawa T, Tanaka K, Sugiura Y, Uehara M et al. (2005)
Large-scale DNA microarray analysis of atopic skin lesions shows
overexpression of an epidermal differentiation gene cluster in the
alternative pathway and lack of protective gene expression in the
cornified envelope. Br J Dermatol 152:146–9
Sumimoto S, Kawai M, Kasajima Y, Hamamoto T (1992) Increased plasma
tumour necrosis factor-alpha concentration in atopic dermatitis. Arch
Dis Child 67:277–9
Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J et al. (2004)
Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of
antimicrobial peptide gene expression. J Immunol 173:2909–12
Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjo A, Torma H, Stahle
M (2005) Vitamin D induces the antimicrobial protein hCAP18 in human
skin. J Invest Dermatol 124:1080–2
Wiedow O, Harder J, Bartels J, Streit V, Christophers E (1998) Antileukopro-
tease in human skin: an antibiotic peptide constitutively produced by
keratinocytes. Biochem Biophys Res Commun 248:904–9
Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K et al. (2006)
IL-22 regulates the expression of genes responsible for antimicrobial
defense, cellular differentiation, and mobility in keratinocytes: a
potential role in psoriasis. Eur J Immunol 36:1309–23
Wollenberg A, Wetzel S, Burgdorf WH, Haas J (2003) Viral infections in
atopic dermatitis: pathogenic aspects and clinical management. J Allergy
Clin Immunol 112:667–74
Zheng Y, Niyonsaba F, Ushio H, Ikeda S, Nagaoka I, Okumura K et al. (2008)
Microbicidal protein psoriasin is a multifunctional modulator of
neutrophil activation. Immunology 124:357–67
www.jidonline.org 649
R Gla¨ser et al.
Psoriasin in Atopic Dermatitis
